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Introduction
In eastern Denmark, as in the rest of the Western world, 
the incidence of oropharyngeal squamous cell carcinomas 
(OPSCC) is increasing, mainly due to the increase in a 
subset of tumors associated with human papillomavirus 
(HPV) infection [1–4]. This group of younger patients 
displays a better overall and progression- free survival as 
well as survival after progression compared with the group 
of cancers induced by smoking and alcohol (e.g., HPV- 
negative) [5]. Smoking and alcohol use are causative fac-
tors for developing OPSCC, and it is likely that competing 
diseases might be another cause of death in this group, 
for example, cardiovascular or pulmonary diseases. 
Furthermore, smoking and alcohol intake may lead to 
the development of secondary malignancies in the head 
and neck region, upper digestive tract, and the respiratory 
system.
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Abstract
Identifying the causes of death in head and neck cancer patients can optimize 
follow- up and therapeutic strategies, but studies in oropharyngeal squamous 
cell carcinoma (OPSCC) patients stratified by HPV status are lacking. We report 
cause- specific mortality in a population- based cohort of patients with OPSCC. 
Patients who had been diagnosed with OPSCC (n = 1541) between 2000 and 
2014 in eastern Denmark were included in the study. Causes of death were 
collected through medical files and the Danish National Cause of Death registry. 
Deaths were grouped as (1) primary oropharyngeal cancer, (2) secondary ma-
lignancies, (3) cardiovascular and pulmonary disease, or (4) other/unspecified. 
The cumulative incidence of death and specific causes of death were determined 
using risk analysis. At follow- up, 723 (47.5%) patients had died. The median 
time to and cause of death were determined: oropharyngeal cancer (n = 432; 
1.00 year), secondary malignancies (n = 131; 2.37 years), cardiovascular and 
pulmonary causes (n = 58; 3.48 years), and unspecified causes (n = 102; 
3.42 years). HPV/p16 status was the strongest predictor of improved survival 
across all causes of death. The only cause of death to decrease in incidence 
over the 2 years after treatment was death from OPSCC. HPV/p16 positivity 
was an independent factor for improved survival across all causes of death in 
patients with OPSCC. In addition, both HPV- positive and HPV- negative OPSCC 
patients faced high 5- and 10- year mortality rates. Implementing secondary 
screening and prevention strategies for late toxicity and mortality are major 
goals in managing the treatment of these patients.
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Although the improved survival of patients with 
HPV- positive tumors is well demonstrated, little is 
known about the actual causes of death. A recent 
study comprising 4245 deaths in 5905 patients treated 
for OPSCC reported that the most common cause of 
death after the primary malignancy was cardiopulmo-
nary diseases followed by secondary malignancies 
[6–10], but the timing and HPV status were not 
reported. In contrast, another study failed to show 
an increased risk of death due to cardiovascular disease 
or secondary malignancies in oropharyngeal cancer 
patients [7].
It remains unclear if and how HPV status and short- 
term toxicity of OPSCC treatment impact mortality. 
Likewise, knowledge is lacking on the long- term outcomes 
of HPV- positive patients because these patients are more 
likely to become long- term survivors and thus have a 
higher risk of experiencing late toxicity. Since HPV- positive 
OPSCC patients typically are younger and have a lower 
consumption of alcohol and tobacco, they might have a 
lower risk of cardiopulmonic disease and secondary malig-
nancies [11, 12].
Identifying the primary causes of death can help opti-
mize follow- up and therapeutic strategies for HPV- positive 
and HPV- negative OPSCC patients. We assessed causes 
of death in HPV- positive and HPV- negative oropharyngeal 
cancer patients from a population- based setting in eastern 
Denmark.
Methods
Patients diagnosed with OPSCC in eastern Denmark 
from 2000 to 2014 were included [3, 4, 13]. Aside 
from the tonsillar and base- of- tongue cases, nonspe-
cific tonsillar squamous cell carcinomas (e.g., soft 
palate) were included in the study. The cohort initially 
consisted of 1541 patients. When collecting data on 
the causes of death, the number was reduced to 1521 
because of losses to follow- up. The patients were 
identified through the Danish Head and Neck Cancer 
group (DAHANCA) database and validated through 
the national Danish Pathology Data Registry (DPDR) 
[3, 4]. An expert head and neck pathologist confirmed 
the diagnosis of OPSCC from a hematoxylin and 
eosin (H&E)- stained section of each tumor. The p16 
staining was considered positive if a strong and dif-
fuse nuclear and cytoplasmic reaction was present 
in more than 75% of the tumor cells [14]. Formalin- 
fixed paraffin- embedded (FFPE) tumor specimens 
were handled according to standard operating pro-
cedures. Immunohistochemistry for p16 was carried 
out using the Ventana Benchmark Ultra autostainer 
with the UltraView detection kit and the p16 
monoclonal antibody E6H4 with CC1 (Roche, Tucson, 
USA). DNA was isolated from two to four 10- μm 
sections using the DSP DNA Mini Kit and the 
QIAsymphony SP kit (Qiagen, Hilden Germany), 
according to the manufacturer’s instructions. HPV- 
DNA PCR was performed using the general primers 
GP5+/6+ and Platinum Taq DNA polymerase 
(Invitrogen, Naerum, Denmark). All samples with a 
negative GP5+/6+ PCR were subject to a GAPDH 
Table 1. Characteristics of patients treated for OPSCC in eastern 
Denmark between 2000 and 2014 (n = 1541).
Median
Absolute 
numbers
Age 60 years
Gender
Female 424
Male 1117
Missing data 0
Status at follow- up (dead/alive)
Alive 801
Dead 738
Missing data 2
Pack-years 30 pack- years
Pack- years category
0 pack- years 341
0–10 pack- years 111
11–20 pack- years 151
More than 20 pack- years 818
Missing data 120
HPV status
HPV- positive 826
HPV- negative 675
Missing data 40
Stage UICC7
Stage 0 0
Stage I 46
Stage II 168
Stage III 345
Stage IV A 860
Stage IV B 81
Stage IV C 32
Missing data 9
Treatment modality
Radiotherapy 783
Radiotherapy + Chemotherapy 613
Palliative treatment 49
No treatment 42
Surgery 24
Other 11
Missing data 19
Performance score
0 772
1 282
2 71
3 27
4 4
Missing data 385
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(housekeeping gene) PCR to confirm DNA quality 
[4, 13]. Tumors were deemed truly HPV- positive 
when they were HPV+/p16+.
Date of death and cause of death were collected from 
each patient’s medical file and the Danish Register of 
Causes of Death (DRCD) [15]. Data from DRCD were 
cross- checked in the medical file when the information 
was implausible (e.g., the cause of death registered as 
an “accident,” even though the patient had been admit-
ted to a hospital due solely to pneumonia). Data from 
the medical file were used as the most plausible infor-
mation. If neither the medical file nor data from the 
DRCD were available, the cause of death was categorized 
as “unspecified.” Medical files were located for 540 patients 
and information from the DRCD was obtained from 
581 patients; thus, 41 patients’ data were only available 
through the DRCD. In total, 157 patients’ files contained 
missing data. The DRCD is updated once a year and 
due to a validating process of the data, the registration 
is performed retrospectively [15]. Patients were followed 
up until 1 October 2016. In Table 3, 709 deaths are 
listed. The remaining 14 deaths were lost to 
follow- up.
Statistical analysis
Patients were categorized into four groups based on the 
cause of death: oropharyngeal cancer, cardiovascular or 
pulmonary causes, secondary malignancy, and unspecified 
causes. The cumulative incidences of death in the four 
Table 2. Characteristics of patients treated for OPSCC in eastern Denmark between 2000 and 2014 by HPV status (n = 1541).
HPV- positive HPV- negative Absolute numbers
Age (median) 59 61
Gender
Female 203 214 417
Male 623 461 1084
Missing data 40
Status at follow- up (dead/alive)
Alive 639 162 801
Dead 286 454 740
Missing data 0
Pack-years (median) 17 41
Pack- years category
0 pack- years 268 57 325
0–10 pack- years 82 28 110
11–20 pack- years 94 55 149
More than 20 pack- years 325 474 799
Missing data 158
Stage UICC7
Stage 0 0 0 0
Stage I 20 24 44
Stage II 73 91 164
Stage III 174 161 335
Stage IV A 494 346 840
Stage IV B 49 29 78
Stage IV C 10 20 30
Missing data 50
Treatment modality
Radiotherapy 368 396 764
Radiotherapy + Chemotherapy 411 187 598
Palliative treatment 11 37 48
No treatment 10 31 41
Surgery 11 11 22
Other 10 0 10
Missing data 58
Performance score
0 516 239 755
1 82 196 278
2 15 55 70
3 4 23 27
4 1 3 4
Missing data 407
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groups were estimated by the Aalen- Johansen method 
[16]. The Cox regression model was used to calculate the 
effect of various covariates on risk of death in the four 
subgroups. The main model included the following covari-
ates: curative treatment as two time- dependent variables 
indicating either current or completed treatment (in con-
trast to no treatment or palliative treatment), age at diag-
nosis, year of diagnosis, gender, HPV- DNA by PCR, p16 
scoring, smoking (pack- years), and UICC7 staging. 
Assumptions of linear effect of quantitative covariates and 
proportional hazards were applied. We analyzed the data 
using Statistical Analysis Software (SAS), version 9.4. This 
study was approved by the Danish DPA and Science Ethics 
Committee.
Results
Patient characteristics
A total of 1541 patients were diagnosed with OPSCC 
between 2000 and 2014 in eastern Denmark. After com-
pleting the data collection, the cohort consisted of 1521 
patients, of whom 723 (47.5%) died during follow- up 
(Tables 1 and 2). The median age was 59 years 
(HPV+:58.3 years; HPV−: 60.1 years) at diagnosis, and 
the median time of follow- up for surviving patients was 
4.88 years (0.25–16.73 years). Most patients were males 
(n = 1,117; 73.4%) and 826 (54.3%) were HPV/p16- positive. 
Tobacco use was high with a median of 30 pack- years. 
Based on the UICC7 classification scheme, 1205 (79.2%) 
patients had stage III or IV OPSCC. For the HPV/p16- 
positive group, based on the UICC8 classification scheme, 
the majority had stage I and II OPSCC (n = 808; 53.1%). 
The majority of patients had a performance status of zero 
(n = 772; 50.8%) or one (n = 282; 18.5%). The most 
common treatment modality was radiotherapy (RT) 
(n = 783; 51.5%) followed by RT with concurrent 
chemotherapy (n = 613; 40.3%). Ninety- one (6%) patients 
received palliative treatment or no treatment at all.
Causes of death in HPV- positive and HPV- 
negative patients
Of the total cohort of deceased patients, 222 (31.3%) were 
HPV/p16 positive (Table 3). In this group, the most com-
mon cause of death was primary OPSCC (n = 129; 58.1%), 
followed by secondary malignancies (n = 37; 16.7%) and 
unspecified causes (n = 32; 14.4%). Twenty- four (10.8%) 
died from cardiovascular or pulmonary diseases. For the 
HPV/p16- negative patients, the most common cause of 
death was primary OPSCC (n = 295; 60.6%), followed 
by secondary malignancies (n = 92; 18.9%) and unspeci-
fied causes (n = 67; 13.8%). Of the HPV- negative patients, 
34 (6.7%) died from cardiovascular or pulmonary 
diseases.
Timing of death and influence of patients 
and disease characteristics
In the total cohort of 723 patients who had died, 434 
(59%) patients died within the first 2 years of OPSCC 
diagnosis, of whom 99 (22.8%) were HPV- positive. Of the 
434 patients, 315 (73%) (n = 72 HPV- positive patients) 
died due to the primary oropharyngeal cancer, followed 
by 51 patients (12%) (n = 8 HPV- positive patients) who 
died due to secondary malignancies. Death due to the 
primary oropharyngeal cancer decreased over time from 
73% in the first 2 years to 23% in the remaining 5 years 
(from year 2 to 7) (P < 0.01) (Figs. 1 and 2), most promi-
nently in the HPV- negative group. There were no significant 
differences in the remaining three subgroups when compar-
ing the hazards ratio of dying within the first 2 years fol-
lowing diagnosis versus within 2–7 years. In addition, when 
stratified by cause of death, there was a 27% and 32% 
Table 3. Cause of death stratified by HPV status and mortality rates.
Cause of death
No. of deaths
Time of 
occurrence (years) 
median (range)
5- year mortality 
(95% CI)
10- year mortality 
(95% CI)HPV- positive HPV- negative Total
Oropharyngeal 
cancer
129 295 424 1.00 
(0.02–14.02)
27 (0.24–0.3) 32 (0.3–0.35)
Secondary cancer 37 92 129 2.37 
(0.076–14.82)
8 (0.07–0.1) 12 (0.1–0.14)
Cardiovascular and 
pulmonary 
diseases
24 33 57 3.47 
(0.08–14.82)
3 (0.02–0.04) 5 (0.04–0.07)
Other/unspecified 
cause of death
32 67 99 3.24 
(0.03–15.27)
5 (0.04–0.06) 9 (0.07–0.11)
Total 222 487 709
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risk of dying from the primary OPSCC, respectively, with 
a 5- and 10- year mortality rate of 8% and a 12% risk of 
dying from a secondary primary cancer (Table 3).
In the subgroup of patients who died from primary 
oropharyngeal cancer, the risk of death was influenced 
by several patient and disease- specific characteristics 
Figure 1. Cumulative incidence of death stratified by cause in HPV-negative patients
Figure 2. Cumulative incidence of death stratified by cause in HPV-positive patients
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(Table 4). In a multivariate analysis, the risk of death 
was higher among HPV−/p16− patients, males, smokers 
with a high number of pack- years, older age, and those 
diagnosed with OPSCC at advanced stages (Table 4). 
Similar results were observed in the other three 
subgroups.
Discussion
To our knowledge, this is the first study to report causes 
of death for HPV- positive and HPV- negative patients 
treated for OPSCC. Our results indicate that being HPV 
and p16 positive is a strong predictor of favorable prog-
nosis across all causes of death. Most patients who died 
from primary OPSCC died within the first 2 years of 
diagnosis, and only 9% (n = 38) of the patients died 
after 5 years. We observed a 5- and 10- year mortality 
rate of 27% and 32%, respectively, due to primary OPSCC. 
The HPV- and p16- negative patients showed a greater 
risk of dying across all causes of death compared to the 
HPV- positive patients.
Van Monsjou et al. reported that OPSCC patients have 
an increased risk of dying from secondary cancers outside 
the head and neck region [6]. They also observed a sig-
nificantly higher risk of dying from pneumonia, cardio-
vascular disease, gastrointestinal disease, or suicide. Baxi 
et al. confirmed that head and neck cancer patients have 
an increased risk of dying from other malignancies and 
cardiovascular diseases [7]. However, neither of these 
studies reported data on HPV or p16 status. In the present 
study, information on the patients’ HPV/p16 status allowed 
precise stratification to analyze causes of death based on 
HPV status.
Screening for secondary malignancy is an important 
factor to reduce mortality, especially when considering 
the high level of tobacco use in the HPV- negative popula-
tion. In our study, we found a 10- year mortality rate of 
12% due to a secondary malignancy. Surprisingly, inten-
sifying the frequency of screenings does not seem to affect 
the number of detected lung cancers, although prolonging 
the screening period may affect lung cancer detection rates 
[17]. Our data indicate that late secondary malignancies, 
namely, lung cancers, are diagnosed frequently in patients 
with OPSCC. In a study from 2007 reporting causes of 
death in patients with oral and oropharyngeal cancer, the 
primary cause of death was recurrence of the primary 
cancer, followed by second primary cancers [18]. Based 
on this finding, the authors recommend more frequent 
follow- ups to increase detection of recurrence and second-
ary cancers. Our study shows a reduced risk of dying 
from secondary malignancies as well as cardiovascular and 
pulmonary diseases among HPV/p16- positive patients 
compared to the HPV- negative subgroup. This finding is 
important because it adds to the knowledge regarding 
the differences among HPV- positive and HPV- negative 
groups and supports the need to individualize follow- ups 
based on the patient’s HPV status.
The strength of our study is the population- based design 
with long- term follow- up with only a small number of 
patients lost to follow- up. Furthermore, we included 
Table 4. Multivariate analysis on cause of death.
Category Index OPSCC CP SM UCD
HR P HR P HR P HR P
Curative 
treatment
0.31 <0.0001 0.94 0.93 0.34 0.004 0.72 0.59
Age 1.02 <0.0001 1.09 <0.0001 1.04 <0.0001 1.04 0.0004
Year of 
diagnosis
0.97 0.01 0.97 0.53 0.88 <0.0001 1 0.1
Gender Female 0.76 0.02 0.66 0.2 0.79 0.29 1.06 0.79
HPV/p16 
status
HPV+/
p16+
0.24 <0.0001 0.39 0.005 0.2 <0.0001 0.2 <0.0001
HPV/p16 
status
HPV+/p16− 0.51 <0.0001 0.28 0.22 1.11 0.73 1.14 0.74
HPV/p16 
status
HPV−/
p16+
0.48 <0.0001 1.25 0.61 0.34 0.01 0.62 0.21
Pack- years 1.01 <0.0001 1.01 0.19 1.01 0.09 1.002 0.61
UICC7 Stage I 0.07 <0.0001 0.68 0.71 0.11 0.01 0.47 0.22
UICC7 Stage II 0.15 <0.0001 1.46 0.63 0.46 0.06 0.46 0.13
UICC7 Stage III 0.27 <0.0001 0.95 0.94 0.38 0.01 0.43 0.08
UICC7 Stage IV 0.45 <0.0001 0.82 0.79 0.45 0.02 0.51 0.13
Category references: Gender, male; HPV/p16 status, HPV−/p16−; UICC7, Stage IV B and C. OPSCC, oropharyngeal squamous cell carcinoma; CP, 
cardiovascular and pulmonary diseases; SM, secondary malignancies; UCD, unspecified cause of death.
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important clinical and nonclinical parameters including 
HPV/p16 status. The treatment of OPSCC has changed 
little over time, making the data from this cohort uniform. 
We acknowledge certain limitations to the study. Since 
doctors who are not necessarily familiar with the patients’ 
medical background register the cause of death in the 
DRCD, the cause of death could be incorrectly registered. 
For instance, if the OPSCC patient suffered from second-
ary malignancies, this secondary malignancy may be reg-
istered as the primary cause of death, even though the 
actual cause is the OPSCC. Likewise, some patients were 
registered as dying of their primary OPSCC 14 years after 
the diagnosis, which is highly unlikely. Notably, this con-
cerns a minority of the patient cohort.
In conclusion, patients with HPV- positive OPSCC face 
a lower risk of dying from all causes of death when com-
pared to the HPV- negative OPSCC patients. Therefore, 
implementing secondary screening and prevention strate-
gies for recurrence of the primary cancer and aiding in 
lifestyle changes to improve recovery are major treatment 
goals. The findings of our study indicate that being HPV 
and p16 positive is an independent factor for improved 
survival across all causes of death, although the 5- and 
10- year mortality rates for both HPV- positive and HPV- 
negative patients are high. Awareness of the patient’s HPV 
status may aid in optimizing and individualizing follow- 
ups in OPSCC patients.
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